FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386554025> ?p ?o ?g. }

• W4386554025 endingPage "1093" @default.
• W4386554025 startingPage "1083" @default.
• W4386554025 abstract "Proton therapy is under investigation in breast cancer as a strategy to reduce radiation exposure to the heart and lungs. So far, studies investigating proton postmastectomy radiotherapy (PMRT) have used conventional fractionation over 25-28 days, but whether hypofractionated proton PMRT is feasible is unclear. We aimed to compare conventional fractionation and hypofractionation in patients with indications for PMRT, including those with immediate breast reconstruction.We did a randomised phase 2 trial (MC1631) at Mayo Clinic in Rochester (MN, USA) and Mayo Clinic in Arizona (Phoenix, AZ, USA) comparing conventional fractionated (50 Gy in 25 fractions of 2 Gy [relative biological effectiveness of 1·1]) and hypofractionated (40·05 Gy in 15 fractions of 2·67 Gy [relative biological effectiveness of 1·1]) proton PMRT. All patients were treated with pencil-beam scanning. Eligibility criteria included age 18 years or older, an Eastern Cooperative Oncology Group performance status of 0-2, and breast cancer resected by mastectomy with or without immediate reconstruction with indications for PMRT. Patients were randomly assigned (1:1) to either conventional fractionation or hypofractionation, with presence of immediate reconstruction (yes vs no) as a stratification factor, using a biased-coin minimisation algorithm. Any patient who received at least one fraction of protocol treatment was evaluable for the primary endpoint and safety analyses. The primary endpoint was 24-month complication rate from the date of first radiotherapy, defined as grade 3 or worse adverse events occurring from 90 days after last radiotherapy or unplanned surgical interventions in patients with immediate reconstruction. The inferiority of hypofractionation would not be ruled out if the upper bound of the one-sided 95% CI for the difference in 24-month complication rate between the two groups was greater than 10%. This trial is registered with ClinicalTrials.gov, NCT02783690, and is closed to accrual.Between June 2, 2016, and Aug 23, 2018, 88 patients were randomly assigned (44 to each group), of whom 82 received protocol treatment (41 in the conventional fractionation group and 41 in the hypofractionation group; median age of 52 years [IQR 44-64], 79 [96%] patients were White, two [2%] were Black or African American, one [1%] was Asian, and 79 [96%] were not of Hispanic ethnicity). As of data cutoff (Jan 30, 2023), the median follow-up was 39·3 months (IQR 37·5-61·2). The median mean heart dose was 0·54 Gy (IQR 0·30-0·72) for the conventional fractionation group and 0·49 Gy (0·25-0·64) for the hypofractionation group. Within 24 months of first radiotherapy, 14 protocol-defined complications occurred in six (15%) patients in the conventional fractionation group and in eight (20%) patients in the hypofractionation group (absolute difference 4·9% [one-sided 95% CI 18·5], p=0·27). The complications in the conventionally fractionated group were contracture (five [12%] of 41 patients]) and fat necrosis (one [2%] patient) requiring surgical intervention. All eight protocol-defined complications in the hypofractionation group were due to infections, three of which were acute infections that required surgical intervention, and five were late infections, four of which required surgical intervention. All 14 complications were in patients with immediate expander or implant-based reconstruction.After a median follow-up of 39·3 months, non-inferiority of the hypofractionation group could not be established. However, given similar tolerability, hypofractionated proton PMRT appears to be worthy of further study in patients with and without immediate reconstruction.The Department of Radiation Oncology, Mayo Clinic, Rochester, MN, the Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, USA, and the US National Cancer Institute." @default.
• W4386554025 created "2023-09-09" @default.
• W4386554025 creator A5005150037 @default.
• W4386554025 creator A5006151030 @default.
• W4386554025 creator A5006416100 @default.
• W4386554025 creator A5006695737 @default.
• W4386554025 creator A5010897991 @default.
• W4386554025 creator A5020773196 @default.
• W4386554025 creator A5023100809 @default.
• W4386554025 creator A5024662261 @default.
• W4386554025 creator A5027044033 @default.
• W4386554025 creator A5030089962 @default.
• W4386554025 creator A5030878252 @default.
• W4386554025 creator A5032135930 @default.
• W4386554025 creator A5033544737 @default.
• W4386554025 creator A5035827527 @default.
• W4386554025 creator A5036038074 @default.
• W4386554025 creator A5043792798 @default.
• W4386554025 creator A5044939667 @default.
• W4386554025 creator A5048853496 @default.
• W4386554025 creator A5052933129 @default.
• W4386554025 creator A5073849902 @default.
• W4386554025 creator A5075103458 @default.
• W4386554025 creator A5088854603 @default.
• W4386554025 date "2023-10-01" @default.
• W4386554025 modified "2023-10-14" @default.
• W4386554025 title "Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial" @default.
• W4386554025 cites W1964536172 @default.
• W4386554025 cites W1985430645 @default.
• W4386554025 cites W2036934183 @default.
• W4386554025 cites W2056532325 @default.
• W4386554025 cites W2083770395 @default.
• W4386554025 cites W2083812135 @default.
• W4386554025 cites W2089810107 @default.
• W4386554025 cites W2096499183 @default.
• W4386554025 cites W2116706051 @default.
• W4386554025 cites W2123426681 @default.
• W4386554025 cites W2129825983 @default.
• W4386554025 cites W2132276884 @default.
• W4386554025 cites W2137757474 @default.
• W4386554025 cites W2152690763 @default.
• W4386554025 cites W2154375587 @default.
• W4386554025 cites W2556659390 @default.
• W4386554025 cites W2567015639 @default.
• W4386554025 cites W2598117381 @default.
• W4386554025 cites W2608358965 @default.
• W4386554025 cites W2908570353 @default.
• W4386554025 cites W2913181387 @default.
• W4386554025 cites W2957958672 @default.
• W4386554025 cites W2971295976 @default.
• W4386554025 cites W2972179148 @default.
• W4386554025 cites W2980775588 @default.
• W4386554025 cites W3124937987 @default.
• W4386554025 cites W3164704591 @default.
• W4386554025 cites W4360615596 @default.
• W4386554025 doi "https://doi.org/10.1016/s1470-2045(23)00388-1" @default.
• W4386554025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37696281" @default.
• W4386554025 hasPublicationYear "2023" @default.
• W4386554025 type Work @default.
• W4386554025 citedByCount "1" @default.
• W4386554025 crossrefType "journal-article" @default.
• W4386554025 hasAuthorship W4386554025A5005150037 @default.
• W4386554025 hasAuthorship W4386554025A5006151030 @default.
• W4386554025 hasAuthorship W4386554025A5006416100 @default.
• W4386554025 hasAuthorship W4386554025A5006695737 @default.
• W4386554025 hasAuthorship W4386554025A5010897991 @default.
• W4386554025 hasAuthorship W4386554025A5020773196 @default.
• W4386554025 hasAuthorship W4386554025A5023100809 @default.
• W4386554025 hasAuthorship W4386554025A5024662261 @default.
• W4386554025 hasAuthorship W4386554025A5027044033 @default.
• W4386554025 hasAuthorship W4386554025A5030089962 @default.
• W4386554025 hasAuthorship W4386554025A5030878252 @default.
• W4386554025 hasAuthorship W4386554025A5032135930 @default.
• W4386554025 hasAuthorship W4386554025A5033544737 @default.
• W4386554025 hasAuthorship W4386554025A5035827527 @default.
• W4386554025 hasAuthorship W4386554025A5036038074 @default.
• W4386554025 hasAuthorship W4386554025A5043792798 @default.
• W4386554025 hasAuthorship W4386554025A5044939667 @default.
• W4386554025 hasAuthorship W4386554025A5048853496 @default.
• W4386554025 hasAuthorship W4386554025A5052933129 @default.
• W4386554025 hasAuthorship W4386554025A5073849902 @default.
• W4386554025 hasAuthorship W4386554025A5075103458 @default.
• W4386554025 hasAuthorship W4386554025A5088854603 @default.
• W4386554025 hasConcept C121608353 @default.
• W4386554025 hasConcept C126322002 @default.
• W4386554025 hasConcept C141071460 @default.
• W4386554025 hasConcept C155806632 @default.
• W4386554025 hasConcept C168563851 @default.
• W4386554025 hasConcept C203092338 @default.
• W4386554025 hasConcept C2777757722 @default.
• W4386554025 hasConcept C2779244869 @default.
• W4386554025 hasConcept C2989005 @default.
• W4386554025 hasConcept C509974204 @default.
• W4386554025 hasConcept C530470458 @default.
• W4386554025 hasConcept C71924100 @default.
• W4386554025 hasConceptScore W4386554025C121608353 @default.
• W4386554025 hasConceptScore W4386554025C126322002 @default.
• W4386554025 hasConceptScore W4386554025C141071460 @default.

• next